Infinium 2 humanhap550

We derived the genotypes for rs7903146 leveraging the data derived from high throughput genome-wide SNP genotyping, using the Illumina Infinium™ II HumanHap550 or Human 610 BeadChip technology (Illumina, San Diego), at one of the three participating sites. Samples were drawn from genome wide datasets that yielded SNPs with call rates <95%, minor allele frequency <1%, missing rate per person <2% and Hardy-Weinberg equilibrium P < 10^-5 in order to assess most accurately the role of rs7903146

Case subjects were defined as subjects with a diagnosis of migraine (ICD9 code: 346.00–346.93) and registered through the EMR of the Children’s Hospital of Philadelphia (CHOP). All patients fulfilled the International Headache Society diagnostic criteria (ICHD-3b) [5 (link)] for migraine. The number of patients diagnosed with migraine with and without aura was provided in Table S1.All blood samples were collected at the time of diagnosis, and most were annotated with clinical information comprising gender and age at diagnosis. Control subjects were recruited from the Philadelphia region through the CHOP Health Care Network, including four primary-care clinics and several group practices and outpatient practices that included well-child visits. Eligibility criteria for control subjects were (i) self-reporting as Caucasian or African American; (ii) availability of 1.5 μg of high-quality DNA from peripheral-blood mononuclear cells; and (iii) no serious underlying medical disorder, including mental disorders (ICD9 code: 290.0–319). The Research Ethics Board of CHOP provided written informed consent from all subjects by nursing and medical assistant staff under the direction of CHOP clinicians. SNP genotyping was performed using the Illumina Infinium II HumanHap550 and Human Quad610 BeadChips.